Literature DB >> 20608012

Assessment of the prevalence of distal symmetrical polyneuropathy and its risk factors among HAART-treated and untreated HIV infected individuals.

Jaffer Shiffa Shurie1, Amare Deribew.   

Abstract

BACKGROUND: The magnitude and risk factors of Distal Sensory Polyneuropathy (DSP) among people living with HIV/AIDS is not well studied in Ethiopia.
OBJECTIVE: The objective of this study is to determine the prevalence of DSP among highly active ante-retroviral (HAART)-treated and Untreated HIV-positive individuals.
METHOD: Cross-sectional study was conducted from July-December 2007 in Jimma University Specialized Hospital. From a total of 2417 HIV infected individuals who were registered in the HIV/AIDS treatment and follow-up clinic of Jimma University Specialized Hospital, 400 were selected randomly. Data was collected using structured questionnaires which contained a brief peripheral neuropathy screening tool of AIDS Clinical Trial Group protocol 5157. We also reviewed records and did essential laboratory investigation. Data was entered into computer and analyzed with using SPSS 12.0.1 statistical software. RESULT: The overall prevalence of DSP among study participant was 34.6% (110/318) of which 81 of 110 (73.6%) were symptomatic and 29 of 110 (26.4%) were asymptomatic. The prevalence of DSP among highly active ante-retroviral HAART-treated was 48% (98/204) and among untreated individuals it was 10.5% (12/114) respectively. The prevalence of DSP among 30 mg stavudine combination HAART regimen users was 43% (52/121) and 74% (40/54) among 40 mg stavudine users. Where as among Zidovudine combination HAART regimen treated individuals, 20.7% (6/29) were found to have DSP. And among recent (<6 months) HAART and isoniazide (as standard anti TB) exposed study participants, 12 (52%) had DSP and among HAART Untreated INH (as standard anti TB) exposed study participants, DSP was found in 2 (25%) of them. Among socio-demographic variables older participants were 5.3 times more likely to develop DSP as compare to young ones.
CONCLUSION: In our study the prevalence of DSP was high. Age and the combined use of high dose stavudine/40 mg were important risk factors for DSP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20608012

Source DB:  PubMed          Journal:  Ethiop Med J        ISSN: 0014-1755


  12 in total

Review 1.  HIV-associated sensory neuropathy: risk factors and genetics.

Authors:  Peter R Kamerman; Antonia L Wadley; Catherine L Cherry
Journal:  Curr Pain Headache Rep       Date:  2012-06

2.  Evaluation of a screening tool for the identification of neurological disorders in rural Uganda.

Authors:  Andy Tran; Kiran T Thakur; Noeline Nakasujja; Gertrude Nakigozi; Alice Kisakye; James Batte; Richard Mayanja; Aggrey Anok; Ronald H Gray; Maria J Wawer; Leah H Rubin; Ned Sacktor; Deanna Saylor
Journal:  J Neurol Sci       Date:  2020-12-24       Impact factor: 3.181

3.  Distal Sensory Peripheral Neuropathy in Human Immunodeficiency Virus Type 1-Positive Individuals Before and After Antiretroviral Therapy Initiation in Diverse Resource-Limited Settings.

Authors:  Alyssa C Vecchio; Christina M Marra; Jeffrey Schouten; Hongyu Jiang; Johnstone Kumwenda; Khuanchai Supparatpinyo; James Hakim; Ned Sacktor; Thomas B Campbell; Srikanth Tripathy; Nagalingeswaran Kumarasamy; Alberto La Rosa; Breno Santos; Marcus T Silva; Cecilia Kanyama; Cindy Firnhaber; Mina C Hosseinipour; Rosie Mngqibisa; Colin Hall; Paola Cinque; Kevin Robertson
Journal:  Clin Infect Dis       Date:  2020-06-24       Impact factor: 9.079

Review 4.  Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.

Authors:  Alexander J Gill; Dennis L Kolson
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

5.  A Prospective Study Assessing Tumour Response, Survival, and Palliative Care Outcomes in Patients with HIV-Related Kaposi's Sarcoma at Queen Elizabeth Central Hospital, Blantyre, Malawi.

Authors:  H Francis; M J Bates; L Kalilani
Journal:  AIDS Res Treat       Date:  2012-03-11

6.  [Neuropathies related to HIV/AIDS: a clinical study in patients infected with HIV a Centre of Excellence HIV/AIDS of the University of Lubumbashi].

Authors:  Joe Katabwa Kabongo; Célestin Kaputu-Kalala-Malu; Oscar Luboya; Valerien Mutombo; Abel Ntambwe; Mala Ali Mapatano; Kavulu Mayamba Mukendi
Journal:  Pan Afr Med J       Date:  2015-04-21

7.  Peripheral neuropathy in HIV-infected and uninfected patients in Rakai, Uganda.

Authors:  Deanna Saylor; Gertrude Nakigozi; Noeline Nakasujja; Kevin Robertson; Ronald H Gray; Maria J Wawer; Ned Sacktor
Journal:  Neurology       Date:  2017-07-05       Impact factor: 9.910

8.  Influence of Age and Neurotoxic HAART Use on Frequency of HIV Sensory Neuropathy.

Authors:  Olajumoke Oshinaike; Akinsegun Akinbami; Oluwadamilola Ojo; Anthonia Ogbera; Njideka Okubadejo; Frank Ojini; Mustapha Danesi
Journal:  AIDS Res Treat       Date:  2012-04-17

9.  Prevalence and clinical characteristics associated with peripheral neuropathy amongst persons on HAART in Busia County, Kenya.

Authors:  John N Mukoma; Joseph M Matheri; Nassib Tawa
Journal:  S Afr J Physiother       Date:  2020-08-25

10.  The role of physiotherapy in the treatment of HIV-related sensory neuropathy: The perceptions and referral practices of physicians.

Authors:  Tania Steyl; Felista T Shayo
Journal:  S Afr J Physiother       Date:  2015-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.